5 things to watch on the ASX 200 on Monday

It looks set to be a good start to the week for Australian investors.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Friday, the S&P/ASX 200 Index (ASX: XJO) had a strong session and charged higher. The benchmark index rose 0.5% to 8,806 points.

Will the market be able to build on this on Monday? Here are five things to watch:

Contented looking man leans back in his chair at his desk and smiles.

Image Source: Getty Images

ASX 200 expected to rise

The Australian share market looks set for a positive start to the week following a solid session on Wall Street on Friday. According to the latest SPI futures, the ASX 200 is expected to open the day 43 points or 0.5% higher. In the United States, the Dow Jones rose 0.3%, the S&P 500 climbed 0.4%, and the Nasdaq pushed 0.3% higher.

Oil prices ease

ASX 200 energy shares including Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) could have a subdued start to the week after oil prices eased on Friday night. According to Bloomberg, the WTI crude oil price was down 0.95% to US$71.41 a barrel and the Brent crude oil price was down 0.4% to US$76.01 a barrel. This couldn't stop oil prices from recording a decent weekly gain amid rising tensions in the Middle East.

Buy Mesoblast shares

Mesoblast Ltd (ASX: MSB) shares could be in the buy zone according to Bell Potter. This morning, the broker has essentially upgraded the biotechnology company's shares to a buy rating (from speculative buy) with a $4.45 price target. This is almost double its current share price. It said: "MSB is expected to commence submission of the various modules of the Biological Licence Application for Rexlemestrocel-L in heart failure and commence recruitment of the adult study in GvHD (for Ryoncil). We expect MSB will also engage in preliminary discussions with distributors for Rexlemestrocel-L in the chronic lower back pain indication, ahead of the phase 3 readout in mid CY27. Investment thesis: TP $4.45 (unchanged) There are no changes to earnings and we retain our $4.45 target price and Buy rating. As MSB is generating strong revenue growth the Speculative risk rating is no longer warranted."

Gold price falls

It could be a soft start to the week for ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) after the gold price softened on Friday night. According to CNBC, the gold futures price was down 0.65% to US$4,113.7 an ounce. Increased interest rate hike bets have been weighing on the precious metal.

Buy Aroa shares

Bell Potter also sees major upside in Aroa Biosurgery Ltd (ASX: ARX) shares at current levels. This morning, the broker has retained its buy rating and $1.09 price target on the biotechnology company's shares. It commented: "Beyond the clinical readouts, 2H CY26 should bring further clarity on the reimbursement environment. Key watchpoints should include the final PFS and OPPS rules following CMS's proposal to retain the current flat-rate methodology for CY27, while any revised DFU/VLU LCDs could further raise the evidence threshold and narrow the reimbursable product set."

Motley Fool contributor James Mickleboro has positions in Woodside Energy Group Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Woman looking at a laptop and thinking.
Broker Notes

4 ASX shares scoring upgrades in the final week of earnings season

Brokers have increased their ratings on Sigma Healthcare, Adairs, Netwealth, and other shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Buy, hold, sell: Netwealth, Sigma Healthcare, and Wesfarmers shares

The team at Morgans has given its verdict on these shares.

Read more »

Smiling kid flexing his muscles.
Broker Notes

3 ASX 200 shares to buy post-results: broker

Morgans has reviewed these companies' FY26 reports and given them a buy rating.

Read more »

ASX board.
ASX Share Market News

Why the ASX 200 is pushing higher as rate hike fears grow

Tech stocks are leading the market rebound today.

Read more »

Small kid giving a thumbs up.
Broker Notes

9 ASX 200 shares with strengthened buy ratings this week

Brokers are positive on Paladin Energy, Coles, WiseTech, Centuria Capital, and other shares.

Read more »

A couple in a supermarket laugh as they discuss which fruits and vegetables to buy
Broker Notes

Buy, hold, sell: Ramsay Health Care, PLS Group, Woolworths shares

Morgans has updated its ratings and 12-month price targets on these 3 ASX 200 shares.

Read more »

Man rocketing in the sky.
Share Gainers

3 ASX 200 stocks, including Paladin Energy, storming higher on earnings results this week

Investors sent Paladin Energy shares and these two popular ASX 200 stocks soaring following strong earnings results.

Read more »

Broker Notes

WiseTech shares are bouncing back. Is it time to buy?

Could there be more upside ahead?

Read more »